Clinical trial
Study In Patients With Dyslipidaemia
NCT00264667 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00264667 |
|---|---|
| Title | Study In Patients With Dyslipidaemia |
| Official title | A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome X |
| Intervention type | Drug |
| Interventions | GW677954 |
| Enrollment | 290 |
| Start date | Dec 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Dec 13, 2005 |
| Last update posted | Oct 28, 2016 |
| Countries | Argentina, Australia, Chile, Costa Rica, India, Latvia, Mexico, New Zealand, Pakistan, Romania, Russia, Slovakia and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: